Paul L Underwood

List of Publications by Year
in descending order

19	641	840776 11	794594 19
papers	citations	h-index	g-index

19	19	19	1137
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Primary Results of the EVOLVE Short DAPT Study. Circulation: Cardiovascular Interventions, 2021, 14, e010144.	3.9	48
2	Safety and efficacy of Everolimusâ€Eluting bioabsorbable Polymerâ€Coated stent in patients with long coronary lesions: The EVOLVE 48 study. Catheterization and Cardiovascular Interventions, 2021, , .	1.7	2
3	Smallâ€vessel PCI outcomes in men, women, and minorities following platinum chromium everolimusâ€eluting stents: Insights from the pooled PLATINUM Diversity and PROMUS Element Plus Postâ€Approval studies. Catheterization and Cardiovascular Interventions, 2019, 94, 82-90.	1.7	10
4	Impact of Race and Ethnicity on the Clinical and Angiographic Characteristics, Social Determinants of Health, and 1-Year Outcomes After Everolimus-Eluting Coronary Stent Procedures in Women. Circulation: Cardiovascular Interventions, 2019, 12, e006918.	3.9	12
5	Clinical outcomes following implantation of the IONâ„¢ paclitaxelâ€eluting platinum chromium coronary stent in routine clinical practice: Results of the ION U.S. postâ€approval study. Catheterization and Cardiovascular Interventions, 2019, 94, 334-341.	1.7	1
6	Outcomes in Women and Minorities Compared With White Men 1 Year After Everolimus-Eluting Stent Implantation. JAMA Cardiology, 2017, 2, 1303.	6.1	46
7	Longâ€term followâ€up of the platinum chromium TAXUS element (ION) stent. Catheterization and Cardiovascular Interventions, 2015, 86, 994-1001.	1.7	6
8	Primary endpoint results of the OMEGA Study: One-year clinical outcomes after implantation of a novel platinum chromium bare metal stent. Cardiovascular Revascularization Medicine, 2015, 16, 65-69.	0.8	14
9	One-year outcomes in 1,010 unselected patients treated with the PROMUS Element everolimus-eluting stent: the multicentre PROMUS Element European Post-Approval Surveillance Study. EuroIntervention, 2015, 10, 1267-1271.	3.2	12
10	Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial. European Heart Journal, 2014, 35, 2821-2830.	2.2	292
11	Racial Differences in Longâ€Term Outcomes after Percutaneous Coronary Intervention with Paclitaxelâ€Eluting Coronary Stents. Journal of Interventional Cardiology, 2013, 26, 49-57.	1.2	20
12	Final 5-year results of the TAXUS ATLAS, TAXUS ATLAS Small Vessel, and TAXUS ATLAS Long Lesion clinical trials of the TAXUS LibertÃ© paclitaxel-eluting stent in de-novo coronary artery lesions. Coronary Artery Disease, 2013, 24, 61-68.	0.7	8
13	Economic Modeling of New Stent Platforms to Evaluate Cost Effectiveness: Analysis of the TAXUS LibertÃ© Versus TAXUS Express Stents. Journal of Interventional Cardiology, 2012, 25, 353-363.	1.2	3
14	Long-Term Benefit of the TAXUS Liberte Stent in Small Vessels and Long Lesions - TAXUS ATLAS Program -. Circulation Journal, 2011, 75, 1120-1129.	1.6	9
15	Propensity-Matched Patient-Level Comparison of the TAXUS LibertÃ© and TAXUS Element (ION) Paclitaxel-Eluting Stents. American Journal of Cardiology, 2011, 108, 828-837.	1.6	15
16	A prospective evaluation of the safety and efficacy of TAXUS Element paclitaxel-eluting coronary stent implantation for the treatment of de novo coronary artery lesions in small vessels: the PERSEUS Small Vessel trial. EuroIntervention, 2011, 6, 920-927.	3.2	28
17	Clinical and Angiographic Outcomes After Treatment of De Novo Coronary Stenoses With a Novel Platinum Chromium Thin-Strut Stent. Journal of the American College of Cardiology, 2010, 56, 264-271.	2.8	66
18	Intracoronary Autologous Blood to Seal a Coronary Perforation. Herz, 2001, 26, 157-160.	1.1	31

#	Article	IF	Citations
19	Initial experience and safety in the treatment of chronic total occlusions with fiberoptic guidance technology: Optical coherent reflectometry. Catheterization and Cardiovascular Interventions, 2001, 54, 180-187.	1.7	18